IMDNA develops research assays for studying innate and adaptive immunity, inflammatory signaling, immune-cell programs, interferon biology, immune regulation, loss of tolerance, immune-mediated tissue responses, and experimental treatment-associated changes.
Research programs can integrate RT-qPCR/qPCR for targeted transcript-level profiling, ELISA for focused quantitative protein biomarker studies, and multiplex bead-based immunoassays for simultaneous cytokine, chemokine, and soluble-protein profiling. Each technology is selected according to the analyte and research question rather than treated as interchangeable.
Explore molecular programs associated with antigen recognition, leukocyte activation, effector function, memory, and immune regulation.
Investigate cytokine, chemokine, interferon, innate-sensing, and tissue-response pathways.
Study autoimmunity, autoinflammation, allergic/type 2 biology, chronic inflammatory states, and altered immune regulation.
Combine RT-qPCR, ELISA, and multiplex protein measurements when scientifically justified.
Support candidate biomarker verification, longitudinal profiling, pathway research, and experimental treatment-response studies.
The immune system integrates innate recognition with adaptive antigen-specific responses. Cytokines and chemokines coordinate cellular activation, recruitment, differentiation, and feedback, while regulatory mechanisms constrain potentially damaging responses. Because these networks are context-dependent, the biological meaning of an immune biomarker depends on cell source, tissue, timing, stimulus, treatment, and the surrounding immune state.
Research may examine pattern-recognition receptors, myeloid-cell responses, complement-associated biology, inflammatory cytokines, interferon programs, chemokine recruitment, natural-killer-cell responses, and early tissue signals that shape adaptive immunity.
Targeted assays can investigate T-cell and B-cell activation, helper-cell differentiation, antibody-associated pathways, cytotoxic effector programs, immunological memory, and regulatory mechanisms.
Inflammation is a coordinated process involving initiating, amplifying, regulatory, tissue-recruitment, and resolution-associated pathways. The same mediator can have different biological effects depending on concentration, receptor expression, cellular source, target tissue, and disease phase.
Immune-mediated pathology may reflect persistent activation, impaired tolerance, altered cytokine signaling, dysregulated innate sensing, abnormal lymphocyte responses, or failure of regulatory mechanisms.
Rather than defining a universal immune-disease signature, IMDNA research assays can be assembled as biologically interpretable pathway modules selected for the experimental question.
Investigate Toll-like receptor, cytosolic-sensing, NF-κB, interferon-regulatory, and other study-specific innate signaling programs.
Research networks involving TNF, IL-1, IL-6 and related downstream signaling associated with inflammatory activation and tissue responses.
Study interferon-stimulated gene expression and IFN–JAK–STAT–IRF-associated antiviral or immune-activation signatures.
Explore IFN-γ-associated responses, TBX21/T-bet-linked programs, macrophage activation, and cellular immune pathways.
Evaluate IL-4/IL-13 signaling, GATA3-linked programs, allergic inflammation, and type 2 immune-response biology.
Investigate IL-17-associated biology, RORC/RORγt-linked pathways, barrier immunity, and inflammatory programs relevant to multiple immune-mediated conditions.
Study FOXP3-associated programs, IL-10/TGF-β-related networks, inhibitory signaling, and immune-homeostasis mechanisms.
Research NK-cell and cytotoxic T-cell effector programs, including granule-mediated cytotoxicity and activation-associated transcriptional signatures.
Profile chemokine/receptor systems that regulate leukocyte recruitment, tissue localization, and inflammatory-cell migration.
Investigate selected inflammasome-associated genes, innate inflammatory signaling, and downstream cytokine activation where appropriate.
Study B-cell activation, differentiation, antibody-associated responses, germinal-center biology, and selected tolerance mechanisms.
Connect immune signaling to epithelial, endothelial, stromal, barrier, repair, and remodeling responses in disease-specific models.
“Immune-mediated disease” is biologically heterogeneous. A defensible research strategy focuses on mechanisms and predefined experimental contrasts rather than assuming that a single transcript, cytokine, or fixed panel is universally disease-specific.
Study loss of self-tolerance, autoreactive lymphocyte programs, interferon signatures, inflammatory effector pathways, and regulatory responses.
Investigate sustained innate and adaptive immune activation across tissue-specific inflammatory settings.
Explore dysregulated innate immune sensing, inflammasome-associated biology, inflammatory cytokine programs, and recurrent innate inflammatory responses.
Study type 2 cytokine signaling, Th2-associated transcriptional programs, eosinophil-associated pathways, immune-cell recruitment, and regulatory responses.
Investigate selected pathways involved in lymphocyte development, immune activation, signaling defects, regulatory networks, or altered host-defense responses in appropriate research models.
Compare molecular and protein responses across biological states, experimental treatments, doses, time points, responder groups, and mechanistic perturbations.
The analytical platform should follow the analyte. Transcript abundance and soluble-protein concentration represent different biological layers; both can be informative, but they require independent analytical validation and should not be treated as interchangeable.
Best suited for: focused immune gene-expression and selected nucleic-acid research.
Development principle: follow MIQE 2.0 for sample handling, reverse transcription, assay specificity, efficiency, controls, normalization, analytical range, analysis, and transparent reporting.
Best suited for: focused quantitative measurement of individual soluble proteins.
Development principle: use fit-for-purpose ligand-binding validation covering calibration/working range, precision, selectivity, dilutional parallelism, matrix effects, recovery where meaningful, stability, and lot performance.
Best suited for: simultaneous measurement of multiple cytokines, chemokines, growth factors, and other soluble immune proteins.
Development principle: validate each analyte in the multiplex context. Dynamic range, minimum required dilution, matrix interference, parallelism, cross-talk, stability, lot effects, and inter-run variability can differ among analytes.
Examples below illustrate pathway-oriented research targets—not diagnostic signatures, not a fixed commercial panel, and not evidence that any marker is specific to one disease.
A defensible immunology biomarker program should be fit for purpose: analytical validation should match how the data will be used, and claims should remain limited to the specimen, platform, biological model, and endpoint actually evaluated.
| Stage | Best-Practice Approach | Scientific Rationale |
|---|---|---|
| 1. Define intended research use | Specify immune process, disease model, analyte, specimen, stimulus/treatment, comparator, timing, and endpoint. | Determines whether RNA, protein, or combined measurements are appropriate. |
| 2. Select biomarkers mechanistically | Use established immunology, high-quality literature, discovery data, and prespecified hypotheses. | Mechanistic selection is more interpretable than assembling unrelated markers solely because they are measurable. |
| 3. Match analyte to technology | Use RT-qPCR for transcripts, ELISA for focused proteins, and bead-based multiplex assays for multianalyte soluble-protein profiling. | mRNA and protein levels can diverge because of translation, secretion, turnover, cellular source, and compartment biology. |
| 4. Define sample context | Distinguish whole blood, PBMCs, sorted cells, tissue, serum, plasma, cell-culture supernatant, or other matrices. | Bulk RNA and soluble proteins can reflect different cell populations and compartments. |
| 5. Characterize analytical performance | Evaluate platform-specific specificity, precision, range, efficiency, matrix effects, interference, parallelism, stability, and multiplex compatibility as appropriate. | Reduces the risk that technical effects are interpreted as immune biology. |
| 6. Establish controls & normalization | Use platform-appropriate negative, positive, process, calibration, and QC materials; validate reference-gene stability for RT-qPCR. | Controls should address actual failure modes of the assay and specimen matrix. |
| 7. Verify biologically | Use appropriate comparators, biological replication, longitudinal sampling, and prespecified analysis where relevant. | Immune signatures are highly sensitive to timing, cell composition, treatment, infection, tissue context, and physiological state. |
| 8. Validate independently | Lock candidate signatures or models and evaluate them in independent samples before broader generalization. | Independent validation is essential before a research signature can be considered broadly reproducible. |
Immunology research requires separation of gene expression, soluble protein abundance, immune-cell frequency, and functional immune activity.
Immune pathways overlap across autoimmunity, infection, allergy, cancer, transplantation, and inflammatory disease. The same cytokine or transcriptional program may be activated for different biological reasons.
Therefore: IMDNA positions these assays for mechanistic, pathway, biomarker, and translational research—not as universal diagnostic or disease-specific molecular signatures.
A rigorous immunology program connects biological mechanism, specimen choice, analyte selection, technology, analytical validation, and independent biological confirmation.
Each technology requires its own validation strategy. RT-qPCR/qPCR should follow current MIQE guidance; ELISA requires fit-for-purpose ligand-binding characterization; and multiplex bead assays require analyte-level validation and standardized execution.
Define collection, anticoagulant/matrix, processing interval, storage, extraction, freeze-thaw exposure, and relevant cell-composition variables.
Evaluate specificity, amplification efficiency, analytical range, reverse transcription, controls, and normalization for the intended sample type.
Assess working range, precision, selectivity, matrix effects, parallelism/recovery where meaningful, stability, and lot performance.
Evaluate analyte-specific ranges, matrix sensitivity, cross-talk, parallelism, low-end variability, protocol dependence, and batch performance.
Use platform-specific controls and validate reference genes rather than assuming constitutive stability under inflammatory or treatment conditions.
Confirm important findings by complementary methods when appropriate and test candidate signatures outside the discovery dataset.
Immune research rarely fits a universal panel. IMDNA can develop integrated research solutions using RT-qPCR/qPCR, ELISA, multiplex bead-based immunoassays, or a scientifically justified combination of these technologies.
Whether your work focuses on innate immunity, adaptive immunity, inflammatory signaling, interferon biology, Th1/Th2/Th17 programs, regulatory immunity, autoimmunity, autoinflammation, allergy, immune dysregulation, biomarker discovery, or experimental treatment response, IMDNA can develop a focused molecular and protein research strategy around your biological question.